Value investing firm Southeastern Asset Management, led by Mason Hawkins, initiated a new position in Abbott Laboratories during the second quarter of 2026. According to a delayed quarterly disclosure filed with the SEC on August 14, the firm acquired 840,750 shares, valued at approximately $76.29 million as of June 30. This new holding immediately constituted a significant 3.98% of Southeastern's reported portfolio.
The investment period covered by the filing coincided with Abbott Labs reporting strong second-quarter financial results, where it beat earnings expectations and raised its full-year guidance. As with all 13F filings, the disclosure reflects a position held at the end of the quarter and does not detail the exact timing or price of the trades.